Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Investor Presentation (May 2024)
22 slides from Aethlon Medical's investor presentation, May 9, 2024
Slide 1: Corporate Presentation
Corporate Presentation May 2024 Nasdaq: AEMD www.AethlonMedical.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
Slide 3: Investment Highlights
Investment Highlights • Developing novel, patented Hemopurifier blood purification device • Early clinical trials have demonstrated virus and EV (extracellular vesicles, which include exosomes) clearance both in vitro and in patients • The FDA has designated the Hemopurifier® as a “Breakthrough Devi
Slide 4: The Aethlon Hemopurifier®
The Aethlon Hemopurifier® FDA Designated “Breakthrough Device” In Viral And Oncology Indications • Safely administered in 164 Hemopurifier sessions in 38 patients1 • Proprietary, patented technology • Has demonstrated clearance of life- threatening viruses • Designed to clear tumor-derived EVs, and
Slide 5: The Hemopurifier® Is Designed To Capture Viruses And Extracellular Vesicles
The Hemopurifier® Is Designed To Capture Viruses And Extracellular Vesicles From A Patient’s Blood Via Extracorporeal Circuit Potential Therapeutic Applications: • Cancer • Life-threatening viral infections • Organ Transplantation 5
Slide 6: Pipeline Targeting Multiple Indications
Pipeline Targeting Multiple Indications Early Feasibility Indication Pre-Clinical Study Expected to begin in Australia Oncology Solid Tumors failing anti- and India, pending Ethics PD-1 Committee approvals India COVID-19 Ongoing Viral Infections Completed HCV Single patient case study, HIV Completed
Slide 7: The Rationale For Removal Of Tumor-derived Extracellular Vesicles
The Rationale Exists For The Removal Of Tumor-derived Extracellular Vesicles By Aethlon’s Hemopurifier® To Treat Cancer Extracellular Vesicles (EVs) are small membrane-bound particles that serve as key mediators of cell-cell communication. They carry lipids, proteins, and nucleic acids, and are rele
Slide 8: In Vitro Removal Of Cancer-Derived EVs Has Been Demonstrated
In Vitro Removal Of Cancer-Derived EVs Has Been Demonstrated1 • Tumor derived EVs were isolated from cancer patient plasma from multiple tumor types and suspended in buffer • Samples were circulated over a scaled-down version of the Hemopurifier® • The scaled down Hemopurifier was effective for clea
Slide 9: Clinical Development Plans Underway In Oncology
Clinical Development Plans Underway In Oncology • Aethlon is planning a safety, feasibility and “dose finding” clinical trial with the Hemopurifier® in patients with stable or progressive malignancies following a 2-month run- in period of anti-PD-1 antibodies (Keytruda, Opdivo) • This trial is desig
Slide 10: Rationale For Hemopurifier Treatment In Severe COVID-19
Recent Scientific & Clinical Literature Provides A Rationale For Hemopurifier Treatment In Severe COVID–19 Infections • COVID viremia is detected in ~34% of patients and is associated with severity, requirement for ICU stay, development of multi-organ failure and poor outcomes1 • Direct viral injury
Slide 11: In Vitro Removal of Clinically Relevant SARS-CoV-2 Variants
In Vitro Removal of Clinically Relevant SARS-CoV-2 Variants by an Affinity Resin Bearing GNA Has Been Demonstrated 1 Seven SARS-CoV2 variants (104 PFU/mL) in Phosphate Buffered Saline (PBS) buffer passed 3X over column of GNA affinity resin (1g) Table 2. Average Column Capture Efficiency for SARS-
Slide 12: Evidence of In Vivo Removal of SARS-CoV-2
Evidence of In Vivo Removal of SARS-CoV-2 1 Viremic Emergency Use patient in the ICU with critical disease • Request received from Hoag Newport Beach Hospital (Usman Shah, M.D.) on 14 JAN 2021 • 67-year-old male with PMH of Tetralogy of Fallot, CAD and DM admitted on 6 JAN 2021 with hypoxia and SOB
Slide 13: Evidence of SARS-CoV-2 Capture and Clearance by Hemopurifier®
Evidence of SARS-CoV-2 Capture and Clearance by Hemopurifier® 1 • Independent Physician Assessment confirmed request for emergency use 14 JAN 2021 VIRAL COPIES NORMALIZED TO RNase P • IRB approval and Signed Inform Consent obtained (14 JAN 2021) Plasma (Copies/mL) • Patient underwent 6-hour 15 minut
Slide 14: Demonstrated Reduction Of Total EVs And Harmful Cargo
Demonstrated Reduction Of Total EVs And Harmful Cargo In An Emergency Use COVID-19 Patient Treated With Hemopurifier®1 Total EV’s and Exosomal2 miRNA over time: Exosomes and miR-424 Exosomes and miR-16 Normalized Exosome miRNA/ml Plasma Normalized Exosome miRNA/ml plasma 0.6 1.4E+12 0.14 1.4E+12 0.5
Slide 15: COVID-19 India Trial Update
COVID-19 India Trial Update: Treatment Of SARS-CoV-2 Infection In Humans With Hemopurifier® Device • Regulatory agency in India approved the use of Hemopurifier® devices for clinical trial use • Studying ICU patients with severe or life-threatening disease • Designed to include up to 15 patients at
Slide 16: Hemopurifier® Clinical Development Summary
Hemopurifier® Clinical Development Summary Oncology Viral Infections • Safety, feasibility and dose • Clinical trial of finding study in solid Hemopurifier® in severe tumors failing anti-PD-1 COVID-19 infection antibodies • Currently underway in India • Planned to be initiated first in Australia and
Slide 17: Hemopurifier® Filtration of Deceased Donor Kidneys
Hemopurifier® filtration of deceased donor kidneys recovered for transplantation represents an exciting opportunity • Kidneys are the most frequently recovered organ from deceased organ donors1 • In the United States in 2023, approximately 30,000 kidneys were recovered from 15,417 deceased donors fo
Slide 18: In Vitro Data Highlights the Hemopurifier's Potential in Kidney Transplantation
In Vitro Data Highlights the Hemopurifier’s® Potential in Kidney Transplantation • Hemopurifier® filtration of kidney perfusates removes noxious agents1 in vitro • Extracellular vesicles2 and harmful cargos • Virus and viral particles (e.g., HCV) • RNA molecules • Cytokines, chemokines and other inf
Slide 19: Aethlon's Patent Portfolio Provides Protection
Aethlon’s patent portfolio provides protection until as early as 2029 (issued patents) and as late as 2042 (if pending applications are granted) United States International • Issued Patents: • Issued Patents: • 3 US patents issued covering extracorporeal removal of • 24 foreign patents covering exos
Slide 20: Key Financial Highlights
Key Financial Highlights • Approximately $8.0 million in cash as of December 31, 2023 • No debt on balance sheet • Approximately 2.6 million shares outstanding as of April 5, 2024 • Market capitalization of $4.5 million as of April 5, 2024 • Trading on Nasdaq under the ticker “AEMD” 20
Slide 21: Senior Management Team Has Extensive Experience
Senior Management Team Has Extensive Experience With Both Medical Devices And Therapeutics Background Experience James B. Frakes, MBA, Interim CEO & Chief Financial Officer • Over 30 years public company CFO experience • Investment banking & venture capital Guy Cipriani, MBA, Chief Operating Officer
Slide 22: Contact Information
Contact Information 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619.941.0360 Nasdaq: AEMD www.AethlonMedical.com This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including: whether and when our prod